- Syndax Pharmaceuticals recently reported that Phase 1/2 SAVE trial data for its all-oral regimen combining Revuforj (revumenib), decitabine/cedazuridine, and venetoclax in heavily pretreated relapsed or refractory AML were published in the Journal of Clinical Oncology and presented at the 2026 European Hematology Association Congress.
- The regimen’s high overall and composite complete remission response rates across NPM1m, KMT2Ar, and NUP98r subgroups, together with meaningful MRD-negativity and post-transplant maintenance use, highlight Revuforj’s potential to influence future treatment patterns in genetically defined AML.
- We’ll now examine how these SAVE trial results, especially the high overall response rate in heavily pretreated AML, may reshape Syndax’s investment narrative.
The future of work is here. Discover the 31 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
Syndax Pharmaceuticals Investment Narrative Recap
To own Syndax, you have to believe Revuforj and Niktimvo can justify today’s valuation despite ongoing losses, and that Revuforj’s genetically defined AML niche is meaningful enough to matter. The SAVE trial’s high response and MRD-negativity rates support Revuforj’s clinical relevance, but they do not clearly change the near term commercial catalyst or the core risk that dependence on two drugs leaves Syndax exposed to regulatory, safety, or competitive shocks.
Among recent updates, the Q1 2026 results stand out next to the SAVE data: Syndax reported US$64.86 million in revenue and a net loss of US$42.67 million while continuing to invest heavily behind Revuforj and Niktimvo. When you set that financial picture beside the SAVE outcomes, the story centers on whether these products can eventually carry the company to profitability without unexpected safety, pricing, or trial setbacks.
But against this encouraging SAVE readout, investors should still pay close attention to the risk that Revuforj’s safety profile and regulatory scrutiny could...
Read the full narrative on Syndax Pharmaceuticals (it's free!)
Syndax Pharmaceuticals' narrative projects $748.0 million revenue and $110.2 million earnings by 2029. This requires 63.1% yearly revenue growth and a $395.6 million earnings increase from -$285.4 million today.
Uncover how Syndax Pharmaceuticals' forecasts yield a $39.50 fair value, a 108% upside to its current price.
Exploring Other Perspectives
The SAVE results sit at the heart of this debate, since the most optimistic analysts were already assuming revenue near US$942.1 million and earnings of about US$182.7 million by 2029, which is far more bullish than consensus and could shift further as views on Revuforj’s risks and post transplant potential evolve.
Explore 6 other fair value estimates on Syndax Pharmaceuticals - why the stock might be worth 49% less than the current price!
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Syndax Pharmaceuticals research is our analysis highlighting 2 key rewards that could impact your investment decision.
- Our free Syndax Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Syndax Pharmaceuticals' overall financial health at a glance.
Interested In Other Possibilities?
Every day counts. These free picks are already gaining attention. See them before the crowd does:
- Find 45 companies with promising cash flow potential yet trading below their fair value.
- Capitalize on the AI infrastructure supercycle with our selection of the 49 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com